Physician profile
Michael A Diamond
NPI 1447242151
$853.33
in general payments reported to CMS, 2019-2025
22 companies · $232 in 2025
The $232 reported for 2025 was less than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $74.80 · 2022: $171 · 2023: $243 · 2024: $133 · 2025: $232.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $608.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $607.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $178.93 | 2023-2024 | Keytruda |
| Biocryst US Sales Co., LLC | $93.96 | 2025 | Orladeyo |
| Incyte Corporation | $90.41 | 2024-2025 | Opzelura, Jakafi |
| Abbvie INC. | $89.00 | 2022 | |
| Novartis Pharmaceuticals Corporation | $49.32 | 2022-2024 | |
| Janssen Biotech, INC. | $43.26 | 2023 | Rybrevant, Darzalex, Imbruvica |
| Takeda Pharmaceuticals U.S.A., INC. | $29.42 | 2025 | Iclusig |
| Astrazeneca Pharmaceuticals LP | $28.70 | 2025 | Enhertu |
| Alnylam Pharmaceuticals INC. | $24.67 | 2024 | Givlaari |
| Recordati_rare_diseases_inc. | $21.91 | 2023 | Sylvant |
| Genentech USA, INC. | $21.64 | 2025 | Phesgo |
| Stemline Therapeutics INC. | $20.82 | 2024 | Orserdu |
| Alexion Pharmaceuticals, INC. | $20.77 | 2023 | Ultomiris |
| Celgene Corporation | $20.62 | 2019 | |
| Jazz Pharmaceuticals INC. | $19.41 | 2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $17.37 | 2024 | Xarelto |
| Sanofi-Aventis U.S. LLC | $16.82 | 2019 | |
| Seagen INC. | $16.77 | 2022 | |
| Amag Pharmaceuticals, INC. | $16.06 | 2019 | |
| Daiichi Sankyo INC. | $13.93 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $12.17 | 2022 | |
| Fortovia Therapeutics, INC. | $7.37 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Diamond listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.